5:22 PM
 | 
Jun 13, 2013
 |  BC Extra  |  Clinical News

Lilly stops AD trial of LY2886721

Eli Lilly and Co. (NYSE:LLY) discontinued the Phase II BACC trial evaluating once-daily oral LY2886721 for 26 weeks in patients with Alzheimer's disease (AD) after cases...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >